Objective: Dilated cardiomyopathy (DCM) is a heart disease with high mortality characterized by progressive cardiac dilation and myocardial contractility reduction. The molecular signature of dilated cardiomyopathy remains to be defined. Hence, seeking potential biomarkers and therapeutic of DCM is urgent and necessary.Methods: In this study, we utilized the Robust Rank Aggregation (RRA) method to integrate four eligible DCM microarray datasets from the GEO and identified a set of significant differentially expressed genes (DEGs) between dilated cardiomyopathy and non-heart failure. Moreover, LASSO analysis was carried out to clarify the diagnostic and DCM clinical features of these genes and identify dilated cardiomyopathy derived diagnostic signatures (DCMDDS).Results: A total of 117 DEGs were identified across the four microarrays. Furthermore, GO analysis demonstrated that these DEGs were mainly enriched in the regulation of inflammatory response, the humoral immune response, the regulation of blood pressure and collagen–containing extracellular matrix. In addition, KEGG analysis revealed that DEGs were mainly enriched in diverse infected signaling pathways. Moreover, Gene set enrichment analysis revealed that immune and inflammatory biological processes such as adaptive immune response, cellular response to interferon and cardiac muscle contraction, dilated cardiomyopathy are significantly enriched in DCM. Moreover, Least absolute shrinkage and selection operator (LASSO) analyses of the 18 DCM-related genes developed a 7-gene signature predictive of DCM. This signature included ANKRD1, COL1A1, MYH6, PERELP, PRKACA, CDKN1A, and OMD. Interestingly, five of these seven genes have a correlation with left ventricular ejection fraction (LVEF) in DCM patients.Conclusion: Our present study demonstrated that the signatures could be robust tools for predicting DCM in clinical practice. And may also be potential treatment targets for clinical implication in the future.

BackgroundUsing circulating biomarkers as a noninvasive method to assist the evaluation of coronary artery disease (CAD) is beneficial for reducing the unnecessary diagnostic cardiac catheterization. This study aimed to assess the predictive role of angiopoietin‐2 (Ang‐2) for the presence of obstructive coronary stenosis as compared with N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) in patients with symptoms of CAD.MethodsThe study enrolled 222 consecutive symptomatic patients who underwent elective diagnostic cardiac catheterization from July to December 2018. Blood samples were collected in the first morning after admission. The severity of coronary stenosis was assessed by coronary angiography. The obstructive CAD was defined as stenosis ≥50% of the left main coronary artery or stenosis ≥70% of a major epicardial vessel (left anterior descending artery, left circumflex artery and right coronary artery).ResultsPatients with obstructive CAD (n = 120) had significantly higher levels of Ang‐2 and NT‐proBNP compared with those without. In multivariable regression analysis, only NT‐proBNP levels were independently associated with Ang‐2 levels. NT‐proBNP was superior to Ang‐2 as a predictor for the presence of obstructive CAD (NT‐proBNP, area under curve [AUC] = 0.733, vs Ang‐2, AUC = 0.626, P = 0.004). In multiple logistic regression analysis, NT‐proBNP, but not Ang‐2, was the independent predictor of obstructive CAD. The combination of Ang‐2 with NT‐proBNP did not provide the incremental value over NT‐proBNP alone.ConclusionSerum Ang‐2 levels are associated with NT‐proBNP levels in patients suspected for CAD. NT‐proBNP is superior to Ang‐2 as a predictor for the presence of obstructive CAD. However, Ang‐2 does not further increase diagnostic accuracy on top of NT‐proBNP.

No abstract